Matches in SemOpenAlex for { <https://semopenalex.org/work/W1999997611> ?p ?o ?g. }
- W1999997611 endingPage "76" @default.
- W1999997611 startingPage "69" @default.
- W1999997611 abstract "Breast cancer is a heterogeneous disease, and within the HER-2 positive subtype this is highly exemplified by the presence of substantial phenotypical and clinical heterogeneity, mostly related to hormonal receptor (HR) expression. It is well known how HER-2 positivity is commonly associated with a more aggressive tumor phenotype and decreased overall survival and, moreover, with a reduced benefit from endocrine treatment. Preclinical studies corroborate the role played by functional crosstalks between HER-2 and estrogen receptor (ER) signaling in endocrine resistance and, more recently, the activation of ER signaling is emerging as a possible mechanism of resistance to HER-2 blocking agents. Indeed, HER-2 positive breast cancer heterogeneity has been suggested to underlie the variability of response not only to endocrine treatments, but also to HER-2 blocking agents. Among HER-2 positive tumors, HR status probably defines two distinct subtypes, with dissimilar clinical behavior and different sensitivity to anticancer agents. The triple positive subtype, namely, ER/PgR/Her-2 positive tumors, could be considered the subset which most closely resembles the HER-2 negative/HR positive tumors, with substantial differences in biology and clinical outcome. We argue on whether in this subgroup the “standard” treatment may be considered, in selected cases, i.e., small tumors, low tumor burden, high expression of both hormonal receptors, an overtreatment. This article review the existing literature on biologic and clinical data concerning the HER-2/ER/PgR positive tumors, in an attempt to better define the HER-2 subtypes and to optimize the use of HER-2 targeted agents, chemotherapy and endocrine treatments in the various subsets." @default.
- W1999997611 created "2016-06-24" @default.
- W1999997611 creator A5001752773 @default.
- W1999997611 creator A5003744289 @default.
- W1999997611 creator A5004436634 @default.
- W1999997611 creator A5004830992 @default.
- W1999997611 creator A5010531543 @default.
- W1999997611 creator A5019614566 @default.
- W1999997611 creator A5020110438 @default.
- W1999997611 creator A5020324515 @default.
- W1999997611 creator A5023710153 @default.
- W1999997611 creator A5025243663 @default.
- W1999997611 creator A5026439843 @default.
- W1999997611 creator A5027075905 @default.
- W1999997611 creator A5034345931 @default.
- W1999997611 creator A5038529742 @default.
- W1999997611 creator A5042989547 @default.
- W1999997611 creator A5065403219 @default.
- W1999997611 creator A5068721926 @default.
- W1999997611 creator A5080721675 @default.
- W1999997611 creator A5087175612 @default.
- W1999997611 creator A5088765472 @default.
- W1999997611 date "2015-02-01" @default.
- W1999997611 modified "2023-10-18" @default.
- W1999997611 title "Triple positive breast cancer: A distinct subtype?" @default.
- W1999997611 cites W1595886999 @default.
- W1999997611 cites W1644299043 @default.
- W1999997611 cites W1873831426 @default.
- W1999997611 cites W1881540319 @default.
- W1999997611 cites W1898692666 @default.
- W1999997611 cites W1961026612 @default.
- W1999997611 cites W1974026856 @default.
- W1999997611 cites W1980601200 @default.
- W1999997611 cites W1983724690 @default.
- W1999997611 cites W1995859582 @default.
- W1999997611 cites W2000468408 @default.
- W1999997611 cites W2000598990 @default.
- W1999997611 cites W2004505325 @default.
- W1999997611 cites W2010714248 @default.
- W1999997611 cites W2017021495 @default.
- W1999997611 cites W2020651525 @default.
- W1999997611 cites W2022938615 @default.
- W1999997611 cites W2025005089 @default.
- W1999997611 cites W2042079804 @default.
- W1999997611 cites W2042174846 @default.
- W1999997611 cites W2043506695 @default.
- W1999997611 cites W2051665090 @default.
- W1999997611 cites W2055139410 @default.
- W1999997611 cites W2058003857 @default.
- W1999997611 cites W2063874882 @default.
- W1999997611 cites W2064823103 @default.
- W1999997611 cites W2067199269 @default.
- W1999997611 cites W2077266258 @default.
- W1999997611 cites W2077363843 @default.
- W1999997611 cites W2078140185 @default.
- W1999997611 cites W2081923162 @default.
- W1999997611 cites W2086224272 @default.
- W1999997611 cites W2089589284 @default.
- W1999997611 cites W2090561517 @default.
- W1999997611 cites W2091205535 @default.
- W1999997611 cites W2092254352 @default.
- W1999997611 cites W2096283457 @default.
- W1999997611 cites W2097255042 @default.
- W1999997611 cites W2097698108 @default.
- W1999997611 cites W2101299592 @default.
- W1999997611 cites W2101824720 @default.
- W1999997611 cites W2105882193 @default.
- W1999997611 cites W2107631501 @default.
- W1999997611 cites W2109462843 @default.
- W1999997611 cites W2111253826 @default.
- W1999997611 cites W2111578514 @default.
- W1999997611 cites W2116760308 @default.
- W1999997611 cites W2116937653 @default.
- W1999997611 cites W2117357260 @default.
- W1999997611 cites W2117873881 @default.
- W1999997611 cites W2119878357 @default.
- W1999997611 cites W2120661754 @default.
- W1999997611 cites W2123591186 @default.
- W1999997611 cites W2127362596 @default.
- W1999997611 cites W2128347157 @default.
- W1999997611 cites W2129110050 @default.
- W1999997611 cites W2131994307 @default.
- W1999997611 cites W2140055441 @default.
- W1999997611 cites W2141217952 @default.
- W1999997611 cites W2141232624 @default.
- W1999997611 cites W2141393790 @default.
- W1999997611 cites W2143937001 @default.
- W1999997611 cites W2145257123 @default.
- W1999997611 cites W2146378328 @default.
- W1999997611 cites W2146383973 @default.
- W1999997611 cites W2147299492 @default.
- W1999997611 cites W2147415463 @default.
- W1999997611 cites W2148105927 @default.
- W1999997611 cites W2150086065 @default.
- W1999997611 cites W2154488022 @default.
- W1999997611 cites W2154591735 @default.
- W1999997611 cites W2155784834 @default.
- W1999997611 cites W2160527585 @default.